Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
DESTINY-Breast07
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- NCT04538742 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DESTINY-Breast07 (trastuzumab deruxtecan; trastuzumab deruxtecan plus durvalumab; trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DESTINY-Breast07 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 16 | |
| YouTube | 10 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan; Durvalumab; Paclitaxel; Pertuzumab; Tucatinib
- Arms
- Module 1- T-DXd and Durvalumab · Experimental
- Module 2- T-DXd and Pertuzumab · Experimental
- Module 3- T-DXd and Paclitaxel · Experimental
- Module 4- T-DXd and Durvalumab and Paclitaxel · Experimental
- Module 0- T-DXd · Experimental
- Module 5 - T-DXd and Tucatanib · Experimental
- Module 6 - T-DXd and Tucatinib · Experimental
- Module 7 - T-DXd · Experimental
- Enrollment
- 245
- Primary outcomes
- Occurrence of adverse events (AEs)- Part 1
- Occurrence of serious adverse events (SAEs)- Part 1
- Occurrence of adverse events (AEs)- Part 2
- Occurrence of serious adverse events (SAEs)- Part 2
- Sponsor
- AstraZeneca with Daiichi Sankyo Company, Limited
- Start
- Dec 28, 2020
- Primary completion
- Jan 31, 2025
- Results posted
- No
- Registry record
- NCT04538742 · updated Dec 8, 2025